Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 2:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 147 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Ophthalmic Solution (Vehicle) Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia

NCT06542497
View directory record Official record
Conditions
Presbyopia
Interventions
0.75% phentolamine ophthalmic solution, Placebo
Drug
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
45 Years to 64 Years
Enrollment
569 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
39
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 26, 2026, 2:24 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)

NCT05134974
View directory record Official record
Conditions
Mydriasis, Dilation
Interventions
Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle
Drug
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
12 Years and older
Enrollment
368 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
15
States / cities
Newport Beach, California • Westminster, California • Delray Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 26, 2026, 2:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease

NCT04030962
View directory record Official record
Conditions
Dry Eye Disease, Dry Eye Syndrome
Interventions
AGN-242428, AGN-231868, AGN-242428 Vehicle, AGN-231868 Vehicle, Lifitegrast 5% Ophthalmic Solution
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 19, 2025 · Synced Sep 26, 2026, 2:24 AM EDT
Completed Phase 2 Interventional Results available

OCS-01 in Treating Inflammation and Pain in Post-cataract Patients

NCT04130802
View directory record Official record
Conditions
Inflammation Corneal, Pain, Postoperative
Interventions
OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL, Placebo
Drug
Lead sponsor
Oculis
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Petaluma, California • Roseburg, Oregon • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 26, 2026, 2:24 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye

NCT05109702
View directory record Official record
Conditions
Dry Eye
Interventions
0.25% Tanfanercept Ophthalmic Solution, Placebo
Drug
Lead sponsor
HanAll BioPharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Phoenix, Arizona • Glendale, California • Newport Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 26, 2026, 2:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Dose-Escalation Study to Evaluate Tolerability, Safety & PK of INO-8875 in Healthy Older-Adult Volunteers

NCT01123772
View directory record Official record
Conditions
Health
Interventions
INO-8875, Placebo control
Drug · Other
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
35 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 29, 2012 · Synced Sep 26, 2026, 2:24 AM EDT
Completed Phase 2 Interventional

Next Generation Rocklatan

NCT06441643
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution, Netarsudil 0.02% Ophthalmic Solution, Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution, AR-17043 Vehicle
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
Garden Grove, California • Inglewood, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 26, 2026, 2:24 AM EDT
Completed Phase 2 Interventional Results available

Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis

NCT01320553
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
SPARC1102 I, SPARC1102 II, SPARC1102 III, Vehicle
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
10 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Sep 26, 2026, 2:24 AM EDT
Completed Phase 2 Interventional

A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)

NCT01275105
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Vehicle, Brimonidine Tartrate 0.01%, Brimonidine Tartrate 0.025%, Oxymetazoline HCl 0.025%
Drug
Lead sponsor
Eye Therapies, LLC
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Sep 26, 2026, 2:24 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract Surgery

NCT00198445
View directory record Official record
Conditions
Postoperative Complications, Cataract
Interventions
Bromfenac, Placebo
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
39
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Irvine, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Sep 26, 2026, 2:24 AM EDT
Completed Phase 2 Interventional

A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP)

NCT00902200
View directory record Official record
Conditions
Elevated Intraocular Pressure
Interventions
AR-12286, AR-12286 vehicle
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
8
States / cities
Pasadena, California • Petaluma, California • Brooksville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 26, 2026, 2:24 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye

NCT04268069
View directory record Official record
Conditions
Dry Eye Disease
Interventions
PL9643 Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Andover, Massachusetts • Raynham, Massachusetts • Shelby, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Sep 26, 2026, 2:24 AM EDT
Not listed Phase 3 Interventional

Study of EBI-005 in Dry Eye Disease (DED)

NCT02405039
View directory record Official record
Conditions
Dry Eye
Interventions
EBI-005, Placebo
Drug
Lead sponsor
Eleven Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Birmingham, Alabama • Newport Beach, California • Hamden, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Sep 26, 2026, 2:24 AM EDT
Completed Phase 3 Interventional

Steroids and Cross-linking for Ulcer Treatment

NCT04097730
View directory record Official record
Conditions
Keratitis Bacterial
Interventions
Moxifloxacin Ophthalmic, Difluprednate Ophthalmic, Riboflavin Ophthalmic, Topical Placebo
Drug · Other
Lead sponsor
Thomas M. Lietman
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
San Francisco, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 26, 2026, 2:24 AM EDT
Completed Phase 2 Interventional Results available

A Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in Subjects With Moderate to Severe Dry Eye Disease

NCT04084483
View directory record Official record
Conditions
Dry Eye Disease
Interventions
K-161, Placebo (Vehicle)
Drug · Other
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Newport Beach, California • Lewiston, Maine • Andover, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Sep 26, 2026, 2:24 AM EDT
Completed Phase 2 Interventional Results available

Phase 2, Multi-center, Randomized, Double- Masked and Placebo-Controlled Study of YP-P10 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (ICECAP 1)

NCT05467293
View directory record Official record
Conditions
Dry Eye
Interventions
0.3% YP-P10 Ophthalmic Solution, 1% YP-P10 Ophthalmic Solution, YP-P10 Placebo Ophthalmic Solution (vehicle)
Drug
Lead sponsor
Yuyu Pharma, Inc.
Industry
Eligibility
Not listed
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Sep 26, 2026, 2:24 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.

NCT05389267
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Kinezodianone R hydrochloride, Placebo
Drug
Lead sponsor
Laboratoires Thea
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Sep 26, 2026, 2:24 AM EDT
Completed Phase 2 Interventional Results available

Study of VVN001 Ophthalmic Solution in Dry Eye Disease

NCT04556838
View directory record Official record
Conditions
Dry Eye
Interventions
VVN001 Ophthalmic Solution 1%, VVN001 Ophthalmic Solution 5%, Vehicle
Drug
Lead sponsor
VivaVision Biotech, Inc
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 26, 2026, 2:24 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease

NCT02218489
View directory record Official record
Conditions
Blepharitis
Interventions
KPI-121, Vehicle
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Birmingham, Alabama • Artesia, California • Mission Hills, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2021 · Synced Sep 26, 2026, 2:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.

NCT00784719
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
CP-690,550, Cyclosporine, CP-690,550 Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
27
States / cities
Chandler, Arizona • Peoria, Arizona • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Sep 26, 2026, 2:24 AM EDT
Completed Phase 2 Interventional

Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis

NCT01120132
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
CsA high dose, CsA low dose, PA, Placebo
Drug
Lead sponsor
Fovea Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Sep 26, 2026, 2:24 AM EDT
Active, not recruiting Phase 3 Interventional

Study of OT-101 in Treating Myopia

NCT04770610
View directory record Official record
Conditions
Myopia, Progressive
Interventions
OT-101 Ophthalmic Solution, Vehicle
Drug
Lead sponsor
Ocumension (Hong Kong) Limited
Other
Eligibility
3 Years to 15 Years
Enrollment
678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
15
States / cities
Colorado Springs, Colorado • Fort Collins, Colorado • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Sep 26, 2026, 2:24 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.

NCT06244316
View directory record Official record
Conditions
Dry Eye Disease
Interventions
rhNGF 5 μg/mL, rhNGF 10 μg/mL, Vehicle (Placebo solution)
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
10
States / cities
Chandler, Arizona • Torrance, California • Colorado Springs, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 26, 2026, 2:24 AM EDT
Completed Phase 2 Interventional Results available

Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances

NCT04004507
View directory record Official record
Conditions
Decrease in Night Vision, Disturbance; Vision, Loss
Interventions
Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Lynbrook, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Sep 26, 2026, 2:24 AM EDT